Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cyclacel Pharmaceuti
(NQ:
CYCCP
)
9.750
+0.750 (+8.33%)
Streaming Delayed Price
Updated: 9:34 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cyclacel Pharmaceuti
< Previous
1
2
Next >
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
August 14, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
August 07, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
June 26, 2024
Lengthens Patent Exclusivity of Plogosertib until August 2040
From
Cyclacel
Via
GlobeNewswire
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
June 04, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
June 03, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
May 14, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
May 08, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
May 02, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 30, 2024
From
Cyclacel
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
April 12, 2024
Via
Benzinga
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
April 01, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 19, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 07, 2024
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
March 06, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
February 20, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
January 30, 2024
From
Cyclacel
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
January 11, 2024
Via
Benzinga
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
January 08, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
January 02, 2024
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
December 22, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
December 18, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces Reverse Stock Split
December 12, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
November 30, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
November 28, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
November 13, 2023
From
Cyclacel
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
November 09, 2023
Via
Benzinga
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
November 07, 2023
From
Cyclacel
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
November 02, 2023
Via
Benzinga
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
August 09, 2023
From
Cyclacel
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.